Background: To evaluate the possibility of preventing endotoxin induced renal damage by p38-MAPK inhibition in a human model.
Design and Methods: Twenty-one healthy young male volunteers received 4 ng/kg Escherichia coli endotoxin as a single dose. Four groups of volunteers received an oral dose of placebo or 350, 700 or 1400 mg RWJ-67657, a p38-MAPK inhibitor, 20 min before endotoxin infusion. Urine samples were collected at set time intervals. The urinary excretion rate of β2-microglobulin and N-acetyl-β-D-glucosaminidase, as indicators of tubular dysfunction was determined.
Results: There was a significant increase of β2-microglobulin and N-acetyl-β-D-glucosaminidase urine excretion rate after endotoxin infusion in the placebo group. p38-MAPK inhibition prevented the increase of markers for tubulopathy.
Conclusions: Endotoxin infusion induces measurable tubular damage. Blocking the p38-MAPK may prevent this damage. The mechanism is unclear, but blocking TNF-α release is a possible explanation.
Wadsworth SA , Cavender DE, Beers SA et al. RWJ-67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J Pharmacol Exp Ther1999; 291: 680—687.
2.
Fijen JW, Tulleken JE, Kobold AC et al. Inhibition of p38 mitogen-activated protein kinase: dose-dependent suppression of leukocyte and endothelial response after endotoxin challenge in humans. Crit Care Med2002; 30: 841—845.
3.
Fijen JW, Kobold AC, de Boer P. et al. Leukocyte activation and cytokine production during experimental human endotoxemia. Eur J Intern Med2000; 11: 89—95.
4.
Fijen JW, Zijlstra JG, de Boer P. et al. Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin Exp Immunol2001; 124: 16—20.
5.
Faas MM, Moes H., Fijen JW et al. Monocyte intracellular cytokine production during human endotoxaemia with or without a second in vitro LPS challenge: effect of RWJ-67657, a p38 MAP-kinase inhibitor, on LPS-hyporesponsiveness. Clin Exp Immunol2002; 127: 337—343.
6.
Iwami KI, Matsuguchi T., Masuda A. et al. Naturally occurring soluble form of mouse Toll-like receptor 4 inhibits lipopolysaccharide signaling. J Immunol2000; 165: 6682—6686.
7.
Hoekman K., Van Nieuwkoop JA, Willemze R.The significance of beta-2 microglobulin in clinical medicine. Neth J Med1985; 28: 551—557.
8.
Price RGMeasurement of N-acetyl-beta-glucosaminidase and its isoenzymes in urine methods and clinical applications. EurJ Clin Chem Clin Biochem1992; 30: 693—705.
9.
Tassi C., Abbritti G., Mancuso F. et al. Activity and isoenzyme profile of N-acetyl-beta-D-glucosaminidase in urine from workers exposed to cadmium. Clin Chim Acta2000; 299: 55—64.
10.
Khan RZ, Badr KFEndotoxin and renal function: perspectives to the understanding of septic acute renal failure and toxic shock. Nephrol Dial Transplant1999; 14: 814—818.
11.
Thijs A., Thijs LGPathogenesis of renal failure in sepsis. Kidney Int Suppl1998; 66: S34—S37.
12.
Ueda N., Shah SVTubular cell damage in acute renal failureapoptosis, necrosis, or both. Nephrol Dial Transplant2000; 15: 318—323.
13.
Knotek M., Rogachev B., Wang W. et al. Endotoxemic renal failure in mice: role of tumor necrosis factor independent of inducible nitric oxide synthase. Kidney Int2001; 59: 2243—2249.
14.
Cunningham PN, Dyanov HM, Park P. et al. Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J Immunol2002; 168: 5817—5823.
